Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Post-refractive IOL Outcomes With Clareon TruPlus

NCT: NCT07610226 · RECRUITING

NCT IDNCT07610226
StatusRECRUITING
Start Date2026-06-25
Completion2027-06-23
SponsorLaser Defined Vision (OTHER)
First posted
Last updated

Brief Summary

This is a prospective, single-arm, single-center, single-surgeon study evaluating the Clareon TruPlus IOL in post-refractive cataract patients. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the PRISQ Questionnaire.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑